# Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)

> **NCT02478398** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1025 (actual)

## Conditions studied

- Rhinitis, Allergic, Seasonal

## Interventions

- **BIOLOGICAL:** Short ragweed pollen allergen extract
- **BIOLOGICAL:** Placebo
- **DRUG:** Self-injectable epinephrine
- **DRUG:** Albuterol/Salbutamol
- **DRUG:** Loratadine
- **DRUG:** Olopatadine
- **DRUG:** Mometasone furoate monohydrate

## Key facts

- **NCT ID:** NCT02478398
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-20
- **Primary completion:** 2018-11-09
- **Final completion:** 2018-11-19
- **Target enrollment:** 1025 (ACTUAL)
- **Last updated:** 2019-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02478398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02478398, "Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02478398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*